COVID-19 cases cause big losses for hospitals

Hospitals are facing “massive losses” treating patients with COVID-19––even with higher reimbursement for service, according to a new study from Strata Decision Technology.

In fact, 97% of health systems are losing an average of $2,800 per case. Worse, some are losing between $8,000 and $10,000, the study found.  Strata Decision used a proxy group of related patient cases and modeled the effect on a sample of U.S. health systems.

Under a proposed 20% increase in Medicare reimbursement specifically for COVID-19 cases, hospitals still lost out. Hospitals still face a loss of $1,200 on average per case with higher a reimbursement rate. Some hospital systems can face between $6,000 and $8,00 in losses.

The main reason for hospital losses is due to the higher-than-usual costs to treat COVID-19 patients. Treatment is complex, requiring intense cleaning regimens, more frequent X-rays and CT scans, shortages of personal protective equipment, as well as higher supply and drug costs, according to Strata. Furthermore, some hospital systems are facing a huge number of patients, stretching their resources thin.

To add insult to injury, hospitals aren’t making revenue on elective surgeries after suspending these procedures to make space for treating COVID-19 patients. This action, which was directed by CMS, prevents cost shifting for hospital systems, as elective surgeries are the primary source of revenue. As much as 90% of hospitals could start to see negative profit margins from COVID-19 patients after canceling elective surgeries.

To combat this enormous cash flow problems for hospitals, Strata recommends additional financial relief from the government and other sources. Namely, Strata urged a 35% increase in Medicaid reimbursement for COVID-19-related cases.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.